Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Phelps, W. C.
space
  arrow  Alexander, K. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REVIEW

Antiviral Therapy for Human Papillomaviruses: Rationale and Prospects

right arrow William C. Phelps, PhD, and Kenneth A. Alexander, MD, PhD

1 September 1995 | Volume 123 Issue 5 | Pages 368-382

Objective: To review the basic virology of human papillomavirus (HPV) and the natural history of HPV infection and to discuss current and potential therapies.

Data Sources: The MEDLINE database (1966 to 1994) was searched to identify English-language articles and abstracts on HPV biology and antiviral chemotherapy.

Study Selection: Peer-reviewed basic science and clinical research studies on the molecular, cellular, and human biology of HPV infection.

Data Extraction: Summaries of data from research studies on the biology of papillomavirus infection and information from review articles on the basic and applied pharmacology of antiviral agents.

Data Synthesis: Papillomavirus infections are very common. Human papillomavirus infections may be asymptomatic or may be manifested in various benign or malignant lesions, most notably anogenital condyloma and anogenital carcinoma. Currently, therapeutic options for HPV infection are limited, expensive, and often ineffective. By understanding the basic virology and natural history of HPV infection, potential sites for pharmacologic intervention can be identified. Although currently available antiviral compounds are inactive against HPV, they serve as models for the rational design of HPV antiviral drugs.

Conclusions: Although HPV infection causes substantial morbidity and expense, uniformly effective therapy for HPV infection is not currently available. Several processes in the HPV infection cycle are appropriate targets for the development of antiviral agents. The development of compounds active against HPV could prevent the benign and malignant diseases associated with HPV infection.

Author and Article Information
space

From Burroughs Wellcome Co., Research Triangle Park, North Carolina, and Duke University Medical Center, Durham, North Carolina.
Acknowledgments: The authors thank Peter Howley, Karl M&129;nger, Lynn Smiley, and John Reardon for their helpful discussion and critical review.
Requests for Reprints: William C. Phelps, MD, Division of Virology, RC2, Burroughs Wellcome Co., 3030 Cornwallis Road, PO Box 12700, Research Triangle Park, NC 27709-2700.
Current Author Addresses: Dr. Phelps: Division of Virology, RC2, Burroughs Wellcome Co., 3030 Cornwallis Road, PO Box 12700, Research Triangle Park, NC 27709-2700.




This article has been cited by other articles:


Home page
CVIHome page
D. Opalka, C. E. Lachman, S. A. MacMullen, K. U. Jansen, J. F. Smith, N. Chirmule, and M. T. Esser
Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay
Clin. Vaccine Immunol., January 1, 2003; 10(1): 108 - 115.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
U. R. Hengge, M. Goos, and R. Arndt
Topical Treatment of Warts and Mollusca with Imiquimod
Ann Intern Med, January 4, 2000; 132(1): 95 - 95.
[Full Text] [PDF]


Home page
J. Virol.Home page
W. I. White, S. D. Wilson, W. Bonnez, R. C. Rose, S. Koenig, and J. A. Suzich
In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16
J. Virol., February 1, 1998; 72(2): 959 - 964.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1995 by the American College of Physicians.